Marshall Wace
EUCR

Marshall Wace’s Eucrates Biomedical Acquisition Corp. Ordinary Shares EUCR Stock Holding History

Marshall Wace’s Portfolio EUCR Stock Details EUCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-963
Closed -$9K – 4286
2021
Q4 		$9K Buy
+963
New +$9.44K ﹤0.01% 3762

Other funds holding EUCR

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
ECU
Eisler Capital (UK) London, United Kingdom $21.7B AUM 0.34% 1-Year Est. Return

Marshall Wace's EUCR Position: Q1 2022 in Review

Marshall Wace sold out of Eucrates Biomedical Acquisition Corp. Ordinary Shares (EUCR) in Q1 2022, closing a stake of 963 shares — an estimated $9K sold.

Marshall Wace first reported a position in EUCR in Q4 2021 and held it in 1 quarter. The position peaked at $9K in Q4 2021. 39 funds tracked by Wall St. Rank hold EUCR as of Q1 2022.

  • Marshall Wace reported no remaining Eucrates Biomedical Acquisition Corp. Ordinary Shares position as of Q1 2022 after selling out during the quarter.
  • Marshall Wace sold 963 Eucrates Biomedical Acquisition Corp. Ordinary Shares shares in Q1 2022, an estimated $9K.
  • Marshall Wace first reported a position in Eucrates Biomedical Acquisition Corp. Ordinary Shares in Q4 2021 and held it in 1 quarter.
  • Marshall Wace's Eucrates Biomedical Acquisition Corp. Ordinary Shares position peaked at $9K in Q4 2021.
  • 39 funds tracked by Wall St. Rank held Eucrates Biomedical Acquisition Corp. Ordinary Shares as of Q1 2022.

Based on Marshall Wace's 13F filing for Q1 2022, filed 16 May 2022.